PT-141 cost in 2026: approved Vyleesi vs the compounded market — what each actually costs

Almost everyone who searches “PT-141 cost” is pricing the wrong thing, or rather, they don’t realize there are two things. Bremelanotide — PT-141’s actual drug name — exists as a genuine FDA-approved product, the autoinjector Vyleesi, and it also exists as the compounded nasal spray and injection vial sold all over telehealth and the research-chemical market. Those two products share a molecule and share almost nothing else about how they’re priced. The approved brand is a specialty drug accessed for one narrow medical use; the compounded version is a cash-pay product sold off-label to a much wider audience. This page is about why they cost worlds apart, and what each transaction is really buying. For what the molecule does and what the trials actually show, start with our PT-141 (bremelanotide) evidence review — we won’t re-derive that here.

The approved brand: Vyleesi, priced as a specialty drug

Vyleesi is the rare peptide on this beat with a real label. It’s a single-use, on-demand subcutaneous autoinjector, approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — an approval earned by two randomized, placebo-controlled phase-3 trials.^[1] That regulatory status is exactly what puts it in a different price universe from everything else sold as “PT-141.” A manufactured, approved injectable for a defined medical condition lands in the specialty-drug tier: the kind of product whose list price runs to hundreds of dollars and which is normally reached through a pharmacy benefit, a manufacturer copay or savings program, or a specialty pharmacy — not paid out of pocket at full sticker.

We’re deliberately not quoting an exact Vyleesi figure, because the cash list price, the copay card, and what an individual plan actually charges diverge wildly and shift over time — confirm the current number with the manufacturer program or your pharmacy. The load-bearing point isn’t the sticker; it’s the category. The brand price reflects a regulated biologic-style drug made for one approved indication, with the supervision and the supply controls that come with a prescription product. Insurance, where it applies at all, applies only to that one approved use in that one population. The moment you step outside it — a man, a general “libido” goal, off-label intent — the insurance pathway evaporates, which is a large part of why the market routed around the brand entirely.

The compounded market: what people are actually buying

Strip away the brand and what’s left is the product nearly all the “buy PT-141” traffic is after: compounded bremelanotide, dispensed through telehealth clinics and compounding pharmacies, and sold off-label for men and for general libido well beyond the approved indication. Here pricing is cash-pay and structured like the rest of the peptide telehealth market — you pay for the medication, a clinician review, and shipping, with no insurance in the picture. Per use, compounded PT-141 typically costs a fraction of the brand autoinjector; the trade-off you’re accepting is off-label, less-supervised use of a product outside the approval that makes Vyleesi reasonable.

How that cash price lands depends heavily on route. The studied, label form is a subcutaneous injection, and compounded injectable vials mirror that — you get a vial of known concentration and dose it per protocol. The cheaper-looking option is the nasal spray, which dodges needles and often carries a lower headline price, but that discount comes with a real catch: intranasal absorption of a peptide is far less predictable than a measured injection, so a lower price per bottle doesn’t cleanly translate to a lower price per effective dose. (It’s worth remembering that an intranasal bremelanotide formulation was actually halted in development over blood-pressure increases — route is not a cosmetic choice.) When you compare nasal-spray and injection prices, you’re not comparing like for like.

The gray market: a cheap sticker on an unpriced risk

Below even the compounded telehealth tier sits the research-chemical market — PT-141 sold as a powder “for research use only, not for human consumption.” The per-vial price is the whole pitch: it can undercut the telehealth route dramatically. But that disclaimer is doing real work. These vials sit outside the prescription and compounding-pharmacy system, with no one verifying identity, dose, or purity. The closest hard data on what that gamble looks like comes from the adjacent, better-studied gray market for GLP-1 drugs: a 2024 market-surveillance study that actually purchased and lab-tested semaglutide sold online without a prescription found unregistered sellers, orders that never arrived, and analyzed content that diverged from the label, with impurities and dose mismatches.^[2] PT-141 bought the same way carries the same structural hazard — you aren’t getting a cheaper version of a known product, you’re getting an unknown one. A low price attached to an unquantified risk isn’t cheap; it’s just unpriced. (To be clear: that’s a cost-versus-risk observation, not a route we recommend — see where to get peptides safely.)

So what does PT-141 actually cost?

The honest answer is that there is no single PT-141 price — there’s a brand price and a compounded price, and they answer different questions. If you are a premenopausal woman with diagnosed HSDD, the relevant cost is Vyleesi at the specialty tier, usually softened by insurance or a manufacturer copay program for that approved use. If you’re among the much larger group buying PT-141 off-label, you’re in the cash-pay compounded market, where the per-use cost is a fraction of the brand — with the catch that you’re paying outside the evidence and outside the approval, and the nasal-spray “discount” partly reflects less-certain dosing rather than a true saving. The gray-market vial is cheapest on the sticker and most expensive on risk.

The smart move is the same one we apply to every peptide: anchor what you pay to what’s actually supported. PT-141 is unusual in having real, approved evidence — but only for one indication. Map any spend against that with our peptide evidence matrix, see how PT-141’s pricing logic fits the broader market in our peptide therapy cost breakdown, and if you decide to proceed, compare legitimate telehealth options on care model and price in our peptide therapy provider comparison.